Drug Discovery
ByCan Hippocratic AI’s Acquisition of Grove AI Trigger the Shift from Fragmented Pilots to a Unified Agentic AI Platform in Biopharma?
Executive SummaryAt the 2026 JPM Healthcare Conference in San Francisco, Hippocratic AI announced the acquisition of Grove AI,…
Innovent and Eli Lilly Expand Strategic Alliance to Advance Immunology and Oncology Innovation
Shanghai, China – February, 2026 – Innovent Biologics Inc today announced a new strategic collaboration with Eli Lilly…
Eli Lilly to Acquire Orna Therapeutics in Deal Valued at Up to $2.4 Billion to Advance In Vivo Cell Therapy Platform
Indianapolis, IN – February 9, 2026 – Eli Lilly and Company today announced it has entered into a…
AstraZeneca Reports 2025 Performance with Strong Brand Momentum Across Core Therapeutic Areas
AstraZeneca today announced its full-year 2025 results, reflecting continued growth across oncology, cardiovascular-renal-metabolism (CVRM), respiratory & immunology, and…
What Drives Novartis’ Pipeline Dominance Through 2030?
Novartis’ clinical pipeline exemplifies a “focus factory” strategy, ruthlessly prioritizing 30+ high-ROI NMEs across five core areas (immunology,…
Is CMS’s Block on Elevance MA Sign‑Ups a Turning Point for Payer Compliance?
The Centers for Medicare & Medicaid Services (CMS) has halted new Medicare Advantage enrollments for Elevance Health, freezing sign‑ups for…
